In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various ...

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

The list recommending customs duty of 5% includes 74 drugs, while another suggesting full exemption has 69 drugs. A separate list for rare disease drugs has 56 names for exemption ...

StudyFormycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206 10.07.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...